SCHEMBL24317344

SCHEMBL24317344

Nc1cc2c3c(cccc3c1)C(=O)N2C1CCC(=O)NC1=O

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 18/20 0.59
DDB1 Q16531 15/20 0.59
IKZF3 Q9UKT9 3/20 0.59
TNF P01375 2/20 0.59
IL1B P01584 2/20 0.59
IKZF1 Q13422 2/20 0.59
TBXA2R P21731 1/20 0.59
ALDH1A1 P00352 1/20 0.59
CHRM2 P08172 1/20 0.59
OPRM1 P35372 1/20 0.59
CYP1A2 P05177 1/20 0.59
TSHR P16473 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
BRD4 O60885 1/20 0.51
BCL2L11 O43521 1/20 0.48
BCL2 P10415 1/20 0.48
MCL1 Q07820 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29533415 1.00 CRBN (0.59) CRBNDDB1IKZF3TNFIL1B
Hydrochloric Acid SCHEMBL27006366 0.99 CRBN (0.58) CRBNDDB1IKZF3TNFIL1B
SCHEMBL24317366 0.91 CRBN (0.60) CRBNDDB1IKZF3TNFIL1B
SCHEMBL23292811 0.90 CRBN (0.65) CRBNDDB1IKZF3TNFIL1B
SCHEMBL29532234 0.87 CRBN (0.60) CRBNDDB1IKZF3TNFIL1B
SCHEMBL29532139 0.87 CRBN (0.60) CRBNDDB1IKZF3TNFIL1B
SCHEMBL24317501 0.87 CRBN (0.60) CRBNDDB1IKZF3TNFIL1B
SCHEMBL27006359 0.87 CRBN (0.60) CRBNDDB1IKZF3TNFIL1B
SCHEMBL24317343 0.86 CRBN (0.59) CRBNDDB1IKZF3TNFIL1B
SCHEMBL24317655 0.86 CRBN (0.59) CRBNDDB1IKZF3TNFIL1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 CRBN 281/4885DDB1 1733/4885IKZF3 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.